BofA upgrades Imperial Brands to Buy, sees FY26 growth concerns fading

Bank of America upgraded Imperial Brands to “buy” from “neutral” and lifted its price target to 3,200p from 2,675p, implying ~17% upside. The note argues concerns that Australia’s excise changes and enforcement have hurt fiscal 2026 earnings are overdone, given Australia is ~4% of group EBIT and it expects a positive earnings contribution again from fiscal 2027. Investors’ focus on resilient pricing and next-generation product growth, plus potential FX tailwinds from H2 2027, supported the bullish re-rating as the shares rose 0.6% to 2,689p.

Analysis

This looks more like a valuation repair trade than a change in end-market trajectory. The market has been paying too much for a small, noisy earnings risk in one geography while underweighting the more durable mechanism: combustible pricing plus buybacks can still offset low-single-digit volume decline for several quarters, which supports cash-flow visibility and keeps the equity from derating further.

The second-order effect is sector-wide. If the thesis on Imperial proves right, it can stabilize sentiment on the entire tobacco complex because investors will infer that excise/enforcement shocks are usually localized rather than systemic. That matters most for the cheaper income names where incremental confidence can translate into multiple expansion; it matters less for higher-quality peers already priced for resilience.

The main risk is that the market is misreading the volume data: if enforcement simply pushes consumption underground, reported pricing can look fine while underlying demand is deteriorating. Another trap is execution in next-gen products; if that growth slows, the path to sustainable EBIT growth becomes too dependent on price hikes, which eventually hits elasticity. FX is a real tailwind, but it is too far out to justify the current re-rating by itself.

Near term, the stock can work into the fiscal 2026 print if management confirms pricing and share gains are intact. Over 6-18 months, the ceiling is still capped by structural volume decline and regulatory overhang, so this is not a franchise re-rate story—just a gap-closing one. The contrarian read is that the move may be underdone if the market has been extrapolating Australia into a wider earnings collapse that the rest of the business can absorb.

Key Decisions for Investors

• Long IMBBY on pullbacks ahead of fiscal 2026 results; target a 10-15% rerating over 1-3 months if guidance confirms pricing durability. Falsify on any EBIT guide cut or evidence that Australia-style volume weakness is spreading.
• Relative-value pair: long IMBBY / short BTI for 1-3 months to isolate valuation catch-up versus a larger, less levered peer. This works only if Imperial is dismissed too cheaply; cover if BTI outperforms on next-gen or US exposure.
• Do not use long-dated calls here unless liquidity is favorable; the cleaner trade is stock or ADR because the catalyst is a fundamentals confirmation, not a binary event.
• Watch for any commentary on illicit trade or market share in Australia at the next print; if those metrics worsen, treat the upgrade as a false start and reduce exposure.